Harnessing the approach of the earliest researchers in immunotherapy and the company's vast experience in developing proprietary immunology platforms, Idera's development program is focused on priming the immune system to play a more powerful role in fighting cancer, ultimately increasing the number of people who can benefit from immunotherapy. Idera also continues to focus on the acquisition, development, and ultimate commercialization of drug candidates for both oncology and rare disease indications characterized by small, well-defined patient populations with serious unmet needs.
Company profile
Ticker
IDRA
Exchange
Website
CEO
Vincent Milano
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
AMGEN • Gilead Sciences • Biogen • Qiagen • Moderna • BioNTech SE • Sana Biotechnology • Ginkgo Bioworks • Bio-Techne • Denali Therapeutics ...
Former names
HYBRIDON INC
SEC CIK
Corporate docs
IRS number
43072298
IDRA stock data
News
12 Health Care Stocks Moving In Thursday's After-Market Session
21 Jul 22
12 Health Care Stocks Moving In Wednesday's After-Market Session
29 Jun 22
This Healthcare Stock Jumps Around 188%, Here's 83 Biggest Movers From Yesterday
28 Jun 22
Why Is NeuroSense Therapeutics Surging By 70%? 46 Stocks Moving In Monday's Mid-Day Session
27 Jun 22
91 Biggest Movers From Friday
13 Jun 22
Press releases
Healthcare Breakthroughs: IDRA, NMLSF, LMLLF, BBI; Life Sciences Leaders Report Latest Advances in Novel Therapeutics for Autism, Oncology, Autoimmune Diseases, and Glaucoma
17 May 22
Thinking about buying stock in Annaly Capital Management, Idera Pharmaceuticals, REE Automotive, Applied UV, or AgriFORCE Growing Systems?
17 May 22
Idera Pharmaceuticals Shares Positive Results from Investigator-Sponsored Trial in Melanoma Patients at Amsterdam UMC
17 May 22
Calendar
5 May 22
9 Aug 22
31 Dec 22
Financial summary
| Quarter (USD) | Mar 22 | Dec 21 | Sep 21 | Jun 21 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Operating income | |||||
| Operating margin | |||||
| Net income | |||||
| Net profit margin | |||||
| Cash on hand | |||||
| Change in cash | |||||
| Diluted EPS |
| Annual (USD) | Dec 21 | Dec 20 | Dec 19 | Dec 18 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Operating income | |||||
| Operating margin | |||||
| Net income | |||||
| Net profit margin | |||||
| Cash on hand | |||||
| Change in cash | |||||
| Diluted EPS |
| Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
|---|---|---|---|---|---|---|
| Cash on hand (at last report) | 27.99M | 27.99M | 27.99M | 27.99M | 27.99M | 27.99M |
| Cash burn (monthly) | 1.52M | 1.38M | 1.39M | 1.82M | 1.52M | 1.63M |
| Cash used (since last report) | 6.53M | 5.94M | 6M | 7.83M | 6.55M | 7.02M |
| Cash remaining | 21.46M | 22.06M | 21.99M | 20.16M | 21.44M | 20.97M |
| Runway (months of cash) | 14.1 | 16.0 | 15.8 | 11.1 | 14.1 | 12.9 |
Recent insider trades
| Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
|---|---|---|---|---|---|---|---|---|---|---|
| 6 Jul 22 | Kirby John J. | Stock Option Common Stock | Grant | Acquire A | No | No | 0.4327 | 66,500 | 28.77K | 66,500 |
| 6 Jul 22 | Milano Vincent | Stock Option Common Stock | Grant | Acquire A | No | No | 0.4327 | 124,000 | 53.65K | 124,000 |
| 6 Jul 22 | Soland Daniel B | Stock Option Common Stock | Grant | Acquire A | No | No | 0.4327 | 66,500 | 28.77K | 66,500 |
| 6 Jul 22 | Lim Bryant David | Stock Option Common Stock | Grant | Acquire A | No | No | 0.4327 | 66,500 | 28.77K | 66,500 |
| 1 Jul 22 | Dougherty Michael R | Common Stock | Grant | Acquire A | No | No | 0.438 | 50,086 | 21.94K | 283,116 |
Institutional ownership, Q1 2022
42.6% owned by funds/institutions
| 13F holders | Current |
|---|---|
| Total holders | 33 |
| Opened positions | 4 |
| Closed positions | 7 |
| Increased positions | 4 |
| Reduced positions | 9 |
| 13F shares | Current |
|---|---|
| Total value | 22.98M |
| Total shares | 22.55M |
| Total puts | 0 |
| Total calls | 76.3K |
| Total put/call ratio | – |
| Largest owners | Shares | Value |
|---|---|---|
| Pillar Pharmaceuticals 6 | 16.75M | $19.93M |
| Castellina Ventures | 2.2M | $1.25M |
| Vanguard | 1.33M | $664K |
| BLK Blackrock | 555.4K | $277K |
| Acadian Asset Management | 457.1K | $228K |
| Geode Capital Management | 373.48K | $186K |
| MS Morgan Stanley | 127.07K | $64K |
| Group One Trading | 112.4K | $56K |
| STT State Street | 109.74K | $55K |
| Commonwealth Equity Services | 86.66K | $43K |
Financial report summary
?Competition
Pfizer • Ionis Pharmaceuticals • Gilead Sciences • Astrazeneca • Dynavax Technologies • Durect • Forte Biosciences • Iovance Biotherapeutics • Chinook Therapeutics • OncoSec MedicalContent analysis
?| Positive | ||
| Negative | ||
| Uncertain | ||
| Constraining | ||
| Legalese | ||
| Litigous | ||
| Readability |
H.S. junior Avg
|
|
New words:
alternative, array, comparison, cure, deficiency, favourable, headcount, inception, January, Leadership, letter, minimum, modification, noncompliance, noteworthy, notification, notifying, prohibiting, protection, RSU, showed, team, threshold, traditional, translated, written
Removed:
abnormal, accomplishment, activating, administering, AEs, affecting, amortized, announce, approach, assuming, attrition, blinded, cancer, care, case, central, challenge, chemotherapy, cohort, colorectal, commercializing, complementary, composition, contemporaneously, controlled, CRC, criteria, cutoff, cutting, decided, declared, decline, deducted, demand, demonstrated, dendritic, departed, depend, depository, design, developmental, difficult, disappointing, discover, distributing, dosage, dosing, dramatically, driven, durable, earliest, eliminated, employing, enrolled, era, event, execute, expand, expanded, experienced, expertise, family, FDA, fluctuate, frequency, function, group, heavily, heralded, hire, immature, immunosuppressive, implement, improve, increasing, initially, injected, instability, intratumorally, investigate, involvement, knowledge, life, line, litigation, low, median, metastatic, mg, microenvironment, microsatellite, mismatch, monotherapy, morale, MSS, multicohort, multiple, objective, oncology, order, organizational, OS, pembrolizumab, percentage, pertaining, pipeline, pivotal, population, produce, progressed, progressing, prospectively, randomization, rapidly, rationale, realization, realized, reallocate, receiving, recent, receptor, RECIST, reduction, regimen, registration, reimbursement, relapsed, remain, repair, replacement, requiring, responding, response, restructuring, reversal, review, secondary, serve, shelf, single, stability, stable, standard, state, stepwise, streamline, succeed, successful, supply, survival, system, target, targeted, therapeutic, TLR, TME, tolerated, topline, treated, triplet, tumor, unanticipated, unforeseen, uninjected, unintended, unsuccessful, variety, volatile, volatility, workforce, yield
Financial reports
Current reports
8-K
Departure of Directors or Certain Officers
24 Jun 22
8-K
Other Events
26 May 22
8-K
Idera Pharmaceuticals Shares Positive Results from Investigator- Sponsored Trial in Melanoma Patients at Amsterdam UMC
17 May 22
8-K
Idera Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Corporate Update
4 May 22
8-K
Idera Pharmaceuticals Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update
31 Mar 22
8-K
Idera Pharmaceuticals Announces Tilsotolimod Updates
14 Dec 21
8-K
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
1 Dec 21
8-K
Idera Pharmaceuticals Reports Third Quarter 2021 Financial Results and Provides Corporate Update
8 Nov 21
8-K
Idera Pharmaceuticals Reports Second Quarter 2021 Financial Results and Provides Corporate Update
9 Aug 21
8-K
Submission of Matters to a Vote of Security Holders
10 Jun 21
Registration and prospectus
S-8
Registration of securities for employees
6 Jul 22
S-8
Registration of securities for employees
6 Jul 22
424B5
Prospectus supplement for primary offering
31 Mar 22
S-3/A
Shelf registration (amended)
18 May 21
424B5
Prospectus supplement for primary offering
3 Sep 20
424B5
Prospectus supplement for primary offering
2 Sep 20
S-3
Shelf registration
4 Aug 20
Other
EFFECT
Notice of effectiveness
26 May 21
CORRESP
Correspondence with SEC
23 May 21
UPLOAD
Letter from SEC
8 Mar 21
EFFECT
Notice of effectiveness
3 Sep 20
CORRESP
Correspondence with SEC
30 Aug 20
EFFECT
Notice of effectiveness
17 Aug 20
CORRESP
Correspondence with SEC
11 Aug 20
UPLOAD
Letter from SEC
10 Aug 20
UPLOAD
Letter from SEC
10 Aug 20
EFFECT
Notice of effectiveness
12 Jun 20
Ownership
4
IDERA PHARMACEUTICALS / Bryant David Lim ownership change
7 Jul 22
4
IDERA PHARMACEUTICALS / DANIEL B SOLAND ownership change
7 Jul 22
4
IDERA PHARMACEUTICALS / VINCENT MILANO ownership change
7 Jul 22
4
IDERA PHARMACEUTICALS / John J. Kirby ownership change
7 Jul 22
4
IDERA PHARMACEUTICALS / MICHAEL R DOUGHERTY ownership change
6 Jul 22
SC 13D/A
IDERA PHARMACEUTICALS / Pillar Pharmaceuticals 6 ownership change
30 Jun 22
4
IDERA PHARMACEUTICALS / MAXINE GOWEN ownership change
27 Jun 22
4
IDERA PHARMACEUTICALS / Mark Alan Goldberg ownership change
27 Jun 22
4
IDERA PHARMACEUTICALS / MICHAEL R DOUGHERTY ownership change
27 Jun 22
4
IDERA PHARMACEUTICALS / JAMES A GERAGHTY ownership change
27 Jun 22
Patents
Utility
Immune Modulation with TLR9 Agonists for Cancer Treatment
24 Mar 22
The present invention relates to methods for treating a tumor, including a metastatic tumor, with TLR9 agonist in combination with an immune checkpoint inhibitor therapy.
Utility
Systems and Methods for Api Request Conversion
24 Mar 22
A method or system for application program interface (API) request conversion, includes generating a plurality of configuration files, each associated with a different API format.
Utility
Immune modulation with TLR9 agonists for cancer treatment
18 Jan 22
The present invention relates to methods for treating a tumor, including a metastatic tumor, with TLR9 agonist in combination with an immune checkpoint inhibitor therapy.
Utility
Systems and methods for API request conversion
11 Jan 22
A method or system for application program interface (API) request conversion, includes generating a plurality of configuration files, each associated with a different API format.
Utility
TLR9 Modulators for Treating Cancer
4 Nov 21
The present disclosure relates to methods for treating cancer in patients having low expression of MHC Class I genes, and in patients having increased serum levels of PD-L2 by administration of a TLR9 agonist.
Transcripts
Reddit threads
Daily Discussion Thread - August 5th, 2022
5 Aug 22
Ford raises dividend 50% to 15 cents a share.
30 Jul 22
Daily Plays May 18, 2022
18 May 22
💰Good morning! #premarket #watchlist 05/17 $IDRA -Positive Results from Investigator-Sponsored Trial, $MITQ -earnings, $BRDS -earnings, $AUVI -Inclusion in a Multi-Million Dollar Contract, $PPSI -earnings ! Check it all in Realtime Stock Screener.
17 May 22
💰Good morning! #premarket #watchlist 05/17 $IDRA -Positive Results from Investigator-Sponsored Trial, $MITQ -earnings, $BRDS -earnings, $AUVI -Inclusion in a Multi-Million Dollar Contract, $PPSI -earnings ! Check it all in Realtime Stock Screener.
17 May 22
Daily Plays May 17, 2022
17 May 22
Daily Discussion Thread - May 5th, 2022
5 May 22
Daily Discussion Thread - May 4th, 2022
4 May 22
Daily Discussion Thread - April 1st, 2022
1 Apr 22
Daily Discussion Thread - March 28th, 2022
28 Mar 22